Keyphrases
Renal Cell Carcinoma
85%
Metastatic Renal Cell Carcinoma (mRCC)
60%
Immune Checkpoint Inhibitors
48%
Nivolumab
26%
Cabozantinib
24%
Dose Increase
24%
Extended Disease
24%
Disease Control
24%
Acute Myeloid Leukemia
24%
Tumorgraft
24%
Survival Outcomes
24%
Kidney Cancer
21%
Tumor
17%
Precision Medicine
15%
Tumor Suppressor Gene
13%
Clinical Outcomes
13%
Checkpoint Inhibitor Colitis
12%
Acute Interstitial Nephritis
12%
Clear Cell Renal Cell Carcinoma (ccRCC)
12%
Putative Drug Targets
12%
Prognostic Potential
12%
Chronic Use
12%
Von Hippel-Lindau Tumor Suppressor
12%
Response Predictors
12%
Therapeutic Potential
12%
Drug Susceptibility Testing
12%
Induction Chemotherapy
12%
Day 14
12%
Disease Assessment
12%
Clinical Decision-making
12%
Predictive Models
12%
Non-small Cell Lung Cancer Patients
12%
Prognostic Biomarker
12%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
12%
Potential Predictors
12%
Proton Pump Inhibitors
12%
NIH Funding
12%
Biomarkers Therapeutic Target
12%
Nephrectomy
12%
Response-outcome
12%
Pathological Response
12%
Surgical Outcomes
12%
Hispanic
12%
Molecular Drivers
12%
Programmed Death-ligand 1 (PD-L1)
12%
Hispanic Men
12%
Atezolizumab
12%
Genetic Determinants
12%
Molecular Genetics
12%
Racial Disparities
12%
Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
100%
Immune Checkpoint Inhibitor
36%
Kidney Metastasis
33%
Neoplasm
26%
Nivolumab
25%
Acute Myeloid Leukemia
24%
Metastatic Carcinoma
19%
Kidney Cancer
17%
Malignant Neoplasm
16%
Retrospective Study
15%
Personalized Medicine
15%
Diseases
14%
Diagnosis
14%
Ex Vivo
14%
Nephrectomy
14%
Immunotherapy
14%
Lung Cancer
13%
Proton-Pump Inhibitor
12%
Clinical Decision Making
12%
Cabozantinib
12%
Hemoptysis
12%
Neutrophil
12%
Interstitial Nephritis
12%
Lymphocyte
12%
Drug Dose Increase
12%
Induction Chemotherapy
12%
Von Hippel-Lindau Tumor Suppressor
12%
Disease Assessment
12%
Tumor Suppressor Gene
12%
Colitis
12%
High Risk Population
12%
4 Iodo 2,5 Dimethoxyamphetamine
12%
Metastatic Kidney Cancer
12%
Drug Sensitivity
12%
Non Small Cell Lung Cancer
12%
Racial Disparity
12%
Seminoma
12%
Testis Cancer
12%
Desmoplastic Melanoma
12%
Differential Diagnosis
12%
Plexiform Neurofibroma
12%
Immunity
11%
Dynamic Contrast-Enhanced MRI
10%
Ipilimumab
9%
Overall Survival
9%
Progression Free Survival
9%
Disease
9%
Somatic Mutation
9%
Cancer Specific Survival
9%
Non Seminomatous Germinoma
9%
Pharmacology, Toxicology and Pharmaceutical Science
Renal Cell Carcinoma
75%
Neoplasm
40%
Diseases
27%
Acute Myeloid Leukemia
24%
Immune Checkpoint Inhibitor
21%
Kidney Metastasis
18%
Chemotherapy
15%
Lung Cancer
13%
Kidney Cancer
12%
Tumor Suppressor Protein
12%
Colitis
12%
Cabozantinib
12%
Proton Pump Inhibitor
12%
Von Hippel Lindau Disease
12%
Nivolumab
12%
Non Small Cell Lung Cancer
12%
Hemoptysis
12%
Atezolizumab
12%
Seminoma
12%
Zirconium 89
12%
Testis Cancer
12%
Immunotherapy
11%
Progression Free Survival
9%
Non Seminomatous Germinoma
9%
Cancer Specific Survival
9%
Biological Marker
8%
Disease Exacerbation
7%
Disease
6%